| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Erlotinib | CCLE | pan-cancer | AAC | 0.27 | 2e-08 |
| mRNA | Gefitinib | GDSC1000 | pan-cancer | AAC | 0.19 | 3e-08 |
| mRNA | lapatinib | GDSC1000 | pan-cancer | AAC | 0.26 | 2e-07 |
| mRNA | Erlotinib | GDSC1000 | pan-cancer | AAC | 0.25 | 1e-06 |
| mRNA | lapatinib | gCSI | pan-cancer | AAC | 0.26 | 5e-06 |
| mRNA | Erlotinib | gCSI | pan-cancer | AAC | 0.27 | 6e-06 |
| mRNA | lapatinib | CCLE | pan-cancer | AAC | 0.2 | 3e-05 |
| mRNA | EKB-569 | GDSC1000 | pan-cancer | AAC | 0.14 | 5e-05 |
| mRNA | Vandetanib | CCLE | pan-cancer | AAC | 0.19 | 0.0001 |
| mRNA | Cetuximab | GDSC1000 | pan-cancer | AAC | 0.13 | 0.0001 |